dabigatran etexilate

Significantly increased dabigatran plasma concentrations, leading to a substantially increased risk of bleeding.

Concomitant use is CONTRAINDICATED due to a significant increase in dabigatran exposure and bleeding risk.

Decreased dabigatran plasma concentrations, leading to reduced anticoagulant effect and increased risk of thrombotic events.

Concomitant use is CONTRAINDICATED. If co-administration cannot be avoided, consider alternative anticoagulants.

Increased dabigatran plasma concentrations, leading to increased risk of bleeding.

Monitor for signs of bleeding. Consider a reduced dose of dabigatran (75 mg twice daily) in patients with moderate renal impairment (CrCl 30-50 mL/min) when co-administered with amiodarone. Avoid co-administration in patients with severe renal impairment.

Increased risk of bleeding (gastrointestinal, intracranial).

Concomitant use should be carefully weighed against the benefits. Monitor closely for signs of bleeding, especially gastrointestinal bleeding. Consider a proton pump inhibitor for gastroprotection.

Decreased dabigatran plasma concentrations, leading to reduced anticoagulant effect and increased risk of thrombotic events.

Avoid co-administration. If co-administration is necessary, monitor for signs of reduced efficacy and consider alternative anticoagulants.

Increased dabigatran plasma concentrations, leading to increased risk of bleeding.

Monitor for signs of bleeding. Consider a reduced dose of dabigatran (75 mg twice daily) in patients with moderate renal impairment (CrCl 30-50 mL/min) when co-administered with clarithromycin. Avoid co-administration in patients with severe renal impairment.

Increased risk of bleeding (gastrointestinal, intracranial).

Concomitant use should be carefully weighed against the benefits. Monitor closely for signs of bleeding, especially gastrointestinal bleeding. Consider a proton pump inhibitor for gastroprotection.

Increased dabigatran plasma concentrations, leading to increased risk of bleeding.

Monitor for signs of bleeding. Consider a reduced dose of dabigatran (75 mg twice daily) in patients with moderate renal impairment (CrCl 30-50 mL/min) when co-administered with itraconazole. Avoid co-administration in patients with severe renal impairment.

Increased dabigatran plasma concentrations, leading to increased risk of bleeding.

Monitor for signs of bleeding. Consider a reduced dose of dabigatran (75 mg twice daily) in patients with moderate renal impairment (CrCl 30-50 mL/min) when co-administered with ketoconazole. Avoid co-administration in patients with severe renal impairment.

Increased risk of bleeding (gastrointestinal, intracranial).

Avoid concomitant use if possible. If co-administration is necessary, monitor closely for signs of bleeding, especially gastrointestinal bleeding. Consider a proton pump inhibitor for gastroprotection.

Decreased dabigatran plasma concentrations, leading to reduced anticoagulant effect and increased risk of thrombotic events.

Avoid co-administration. If co-administration is necessary, monitor for signs of reduced efficacy and consider alternative anticoagulants.

Increased dabigatran plasma concentrations, leading to increased risk of bleeding.

Monitor for signs of bleeding. Consider a reduced dose of dabigatran (75 mg twice daily) in patients with moderate renal impairment (CrCl 30-50 mL/min) when co-administered with quinidine. Avoid co-administration in patients with severe renal impairment.